The 31-gene signature derived by Kim et al. has been assessed in HNSCC in a single study and more extensively in primary brain tumours (glioma grade 2–3 and WHO grade IV glioblastoma) alone and in combination with immune status [PD-L1 (CD274 RNA expression)]. This evidence concerns the gene CD274 and central nervous system cancer.